Skip to main content
FOCIS 2025 Main banner
Final Program


Final Program
ViewAttendees 2

Session: Immuno-oncology

Type 2 Immunity May Hold Key to Long-term Cancer Remission

Friday, June 27, 2025
2:00pm - 2:25pm East Coast USA Time
Location: Salons F-G

    Speaker(s)

  • Li Tang, PhD

    Associate Professor
    École Polytechnique Fédérale de Lausanne

Disclosure(s):
Li Tang, PhD: No relevant disclosure to display

Learning Objectives:

  • Upon completion, participants will be able to realize a new paradigm for designing next-generation cancer immunotherapy which synergizes type 1 and type 2 immunity.
  • Upon completion, participants will be able to learn new immunology of cytokines, e.g., IL-4, IL-10, conventionally regarded as immune suppressive.
  • Upon completion, participants will be able to appreciate that IL-10-secreting CAR-T cells exhibit outstanding anticancer efficacy in the clinic for the treatment of B cell malignancies (100% CR at 1% of typical CAR-T cell dose).